title: Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
abstract: OBJECTIVE
  To evaluate neonatal screening for cystic fibrosis (CF), including study of the screening procedures and characteristics of false-positive infants, over the past 10 years in Wisconsin. An important objective evolving from the original design has been to compare use of a single-tier immunoreactive trypsinogen (IRT) screening method with that of a two-tier method using IRT and analyses of samples for the most common cystic fibrosis transmembrane regulator (CFTR) (DeltaF508) mutation. We also examined the benefit of including up to 10 additional CFTR mutations in the screening protocol.
  
  
  METHODS
  From 1985 to 1994, using either the IRT or IRT/DNA protocol, 220 862 and 104 308 neonates, respectively, were screened for CF. For the IRT protocol, neonates with an IRT >/=180 ng/mL were considered positive, and the standard sweat chloride test was administered to determine CF status. For the IRT/DNA protocol, samples from the original dried-blood specimen on the Guthrie card of neonates with an IRT >/=110 ng/mL were tested for the presence of the DeltaF508 CFTR allele, and if the DNA test revealed one or two DeltaF508 alleles, a sweat test was obtained.
  
  
  RESULTS
  Both screening procedures had very high specificity. The sensitivity tended to be higher with the IRT/DNA protocol, but the differences were not statistically significant. The positive predictive value of the IRT/DNA screening protocol was 15.2% compared with 6.4% if the same samples had been screened by the IRT method. Assessment of the false-positive IRT/DNA population revealed that the two-tier method eliminates the disproportionate number of infants with low Apgar scores and also the high prevalence of African-Americans identified previously in our study of newborns with high IRT levels. We found that 55% of DNA-positive CF infants were homozygous for DeltaF508 and 40% had one DeltaF508 allele. Adding analyses for 10 more CFTR mutations has only a small effect on the sensitivity but is likely to add significantly to the cost of screening.
  
  
  CONCLUSIONS
  Advantages of the IRT/DNA protocol over IRT analysis include improved positive predictive value, reduction of false-positive infants, and more rapid diagnosis with elimination of recall specimens.
authors.affiliation: Waisman Center for Mental Retardation and Human Development, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Gregg
authors.forename: A
authors.initials: A
authors.lastname: Simantel
authors.forename: P M
authors.initials: PM
authors.lastname: Farrell
authors.forename: R
authors.initials: R
authors.lastname: Koscik
authors.forename: M R
authors.initials: MR
authors.lastname: Kosorok
authors.forename: A
authors.initials: A
authors.lastname: Laxova
authors.forename: R
authors.initials: R
authors.lastname: Laessig
authors.forename: G
authors.initials: G
authors.lastname: Hoffman
authors.forename: D
authors.initials: D
authors.lastname: Hassemer
authors.forename: E H
authors.initials: EH
authors.lastname: Mischler
authors.forename: M
authors.initials: M
authors.lastname: Splaingard
mesh_terms: D001034:Apgar Score; D019411:Clinical Laboratory Techniques; D003550:Cystic Fibrosis / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D004247:DNA / Q000032:analysis*; D006801:Humans; D007231:Infant, Newborn; D008403:Mass Screening / Q000379:methods; D009154:Mutation; D011237:Predictive Value of Tests; D011863:Radioimmunoassay; D012680:Sensitivity and Specificity; D014362:Trypsinogen / Q000032:analysis*; D014922:Wisconsin
chemical_list: C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D014362:Trypsinogen; D004247:DNA